Telekes András, Deme Dániel
Onkológia, Bajcsy-Zsilinszky Kórház Budapest, Maglódi út 89-91., 1106.
Onkológia, Szent Lázár Megyei Kórház Salgótarján.
Orv Hetil. 2016 Oct;157(40):1587-1594. doi: 10.1556/650.2016.30535.
Ramucirumab is a humanized monoclonal antibody against vascular endothelial growth factor receptor-2, which inhibits the binding of vascular endothelial growth factor-A, -C and -D ligands. Furthermore it blocks the ligand stimulated activation of p44/p42 mitogen activated protein kinases, thus neutralizing the ligand induced proliferation and migration of human endothelial cells. Based on the results of the REGARD (Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma) and the RAINBOW (Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma) studies ramucirumab was approved for 2nd line treatment as monotherapy and in combination with paclitaxel for patients with local relapse and unresectable or metastatic gastric cancer (including gastro-esophegal junction adenocarcinoma). Based on the results, in advanced solid malignancies, ramucirumab may prolong progression free survival and overall survival, although it may increase the risk of all adverse events (fatigue, neutropenia, haemorrhage, nausea, stomatitis). The authors review the clinical studies of ramucirumab. Orv. Hetil., 2016, 157(40), 1587-1594.
雷莫西尤单抗是一种针对血管内皮生长因子受体-2的人源化单克隆抗体，它可抑制血管内皮生长因子-A、-C和-D配体的结合。此外，它还能阻断配体刺激的p44/p42丝裂原活化蛋白激酶的激活，从而中和配体诱导的人内皮细胞增殖和迁移。基于REGARD（雷莫西尤单抗单药治疗既往治疗过的晚期胃癌或胃食管交界腺癌）和RAINBOW（雷莫西尤单抗联合紫杉醇对比安慰剂联合紫杉醇治疗既往治疗过的晚期胃癌或胃食管交界腺癌）研究的结果，雷莫西尤单抗被批准用于局部复发且不可切除或转移性胃癌（包括胃食管交界腺癌）患者的二线单药治疗以及与紫杉醇联合治疗。基于这些结果，在晚期实体恶性肿瘤中，雷莫西尤单抗可能会延长无进展生存期和总生存期，尽管它可能会增加所有不良事件（疲劳、中性粒细胞减少、出血、恶心、口腔炎）的风险。作者回顾了雷莫西尤单抗的临床研究。《匈牙利医学周报》，2016年，157(40)，1587 - 1594。
